• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

作者信息

Fernández‑Balsells M Mercè, Sojo-Vega Lidia, Ricart-Engel Wifredo

机构信息

Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain

Institut Català de la Salut, Girona, Spain

出版信息

N Engl J Med. 2017 Nov 23;377(21):2098. doi: 10.1056/NEJMc1712572.

DOI:10.1056/NEJMc1712572
PMID:29182249
Abstract
摘要

相似文献

1
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
N Engl J Med. 2017 Nov 23;377(21):2098. doi: 10.1056/NEJMc1712572.
2
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
N Engl J Med. 2017 Nov 23;377(21):2097-8. doi: 10.1056/NEJMc1712572.
3
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
N Engl J Med. 2017 Nov 23;377(21):2098-9. doi: 10.1056/NEJMc1712572.
4
Canagliflozin and cardiovascular and renal events in type 2 diabetes.卡格列净与2型糖尿病患者的心血管及肾脏事件
Postgrad Med. 2018 Mar;130(2):149-153. doi: 10.1080/00325481.2018.1423852. Epub 2018 Jan 12.
5
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与2型糖尿病患者的心血管及肾脏事件
N Engl J Med. 2017 Nov 23;377(21):2099. doi: 10.1056/NEJMc1712572.
6
Renal effects of canagliflozin in type 2 diabetes mellitus.卡格列净对2型糖尿病患者的肾脏影响。
Curr Med Res Opin. 2015 Dec;31(12):2219-31. doi: 10.1185/03007995.2015.1092128. Epub 2015 Oct 23.
7
Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.钠-葡萄糖协同转运蛋白2抑制剂卡格列净对2型糖尿病合并慢性肾脏病患者的肾脏保护作用：一项随机开放标签前瞻性试验。
Diab Vasc Dis Res. 2018 Sep;15(5):469-472. doi: 10.1177/1479164118782872. Epub 2018 Jun 20.
8
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.2型糖尿病患者使用钠-葡萄糖协同转运蛋白2抑制剂卡格列净后的生殖器真菌感染：临床研究的汇总分析
Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.
9
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.卡格列净治疗2型糖尿病合并慢性肾脏病患者52周的疗效与安全性
Diabetes Obes Metab. 2014 Oct;16(10):1016-27. doi: 10.1111/dom.12348. Epub 2014 Jul 22.
10
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.一项旨在测试卡格列净在伴有慢性心力衰竭的糖尿病患者中的安全性和非劣效性的随机试验的原理与设计：CANDLE试验
Cardiovasc Diabetol. 2016 Apr 4;15:57. doi: 10.1186/s12933-016-0381-x.

引用本文的文献

1
Type 2 diabetes mediated heart failure: focus on early recognition and clinical strategies.2型糖尿病介导的心力衰竭：聚焦早期识别与临床策略
Front Endocrinol (Lausanne). 2025 Sep 10;16:1630686. doi: 10.3389/fendo.2025.1630686. eCollection 2025.
2
Mechanisms and therapeutics of insulin signaling transduction genes in diabetic cardiomyopathy: a comprehensive updated review.糖尿病性心肌病中胰岛素信号转导基因的机制与治疗：全面更新综述
Front Endocrinol (Lausanne). 2025 Jul 17;16:1589695. doi: 10.3389/fendo.2025.1589695. eCollection 2025.
3
SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges.
钠-葡萄糖协同转运蛋白2抑制剂在自身免疫性疾病中的应用：新出现的治疗潜力与临床挑战
Front Immunol. 2025 Jul 3;16:1589341. doi: 10.3389/fimmu.2025.1589341. eCollection 2025.
4
Novel glucose-lowering agents that benefit diabetic foot: icing on the cake.对糖尿病足有益的新型降糖药物：锦上添花。
Front Endocrinol (Lausanne). 2025 Jul 2;16:1581403. doi: 10.3389/fendo.2025.1581403. eCollection 2025.
5
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.SGLT2 抑制剂对患者结局的影响：网状荟萃分析。
Cardiovasc Diabetol. 2023 Oct 27;22(1):290. doi: 10.1186/s12933-023-02035-8.
6
Current Status of Dapagliflozin in Congestive Heart Failure.达格列净在充血性心力衰竭中的现状
Cureus. 2022 Sep 21;14(9):e29413. doi: 10.7759/cureus.29413. eCollection 2022 Sep.